I had the chance to meet up with Andrew Schorr in Germany at the IWCLL meeting. We taped this interview to provide an overview of where the new CLL drugs may best fit into an individuals treatment plan. Hopefully it is a good summary for you and puts things into a more focused perspective.
Andrew does a great job collecting the voices of many experts and putting them into one place. If you haven't made a contribution to his efforts, you might want to think about doing so. We are lucky to have him out on the front lines.
I apologize for being a little long winded in response to his questions. So much exciting stuff to talk about, I had a hard time containing myself.
